Nostrum signs licensing agreement with IMTECH
Pursuant to such agreement, Nostrum will in-license thrombolytics from IMTECH for clinical development and worldwide commercialisation. Nostrum president Nirmal Mulye said that the new thrombolytics are clot specific
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.